secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2026-06-16T11:34:21+00:00
Accession:  0001628280-26-043416
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen nominates two EBD Alzheimer's candidates (ACU301, ACU401); IND in mid-2027
--------------------------------------------------------------------------------

- Nominated ACU301 (bispecific from sabirnetug) and ACU401 (novel AβO-selective antibody ACU234).
- Exercised option under JCR collaboration; combines Acumen's AβO antibody with J-Brain Cargo BBB-penetrating tech.
- Preclinical data: 14-40x higher brain penetration in NHPs vs native antibodies; low anemia risk; no adverse events.
- IND-enabling activities ongoing; IND submission targeted mid-2027; SC dosing suitability demonstrated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026043416/0001628280-26-043416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026043416/abos-20260612.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-043416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer